FDA Extends PDUFA Date for Lantheus' LNTH-2501 by Three Months
summarizeSummary
The FDA has extended the Prescription Drug User Fee Act (PDUFA) goal date for Lantheus' LNTH-2501 (Ga 68 edotreotide) by three months, pushing the new target to June 29, 2026. This extension allows the FDA additional time to review manufacturing-related information and is explicitly stated not to be related to the product's efficacy or safety data. While the reason for the delay is not clinical, this setback postpones the potential market approval and commercialization of this PET diagnostic imaging kit for neuroendocrine tumors, impacting the company's near-term product pipeline and revenue expectations.
At the time of this announcement, LNTH was trading at $80.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.2B. The 52-week trading range was $47.25 to $108.91. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.